‘Scum of the earth’: Opioid victims face Purdue Pharma owners

Under court rules, the Sacklers were not allowed to respond to the victims, who were selected by lawyers for creditors in the case. Some victims spoke from a law office in New York; others were at their homes or offices around the country.

Jannette Adams told of her late husband, Dr Thomas Adams, who was a physician and church deacon in Mississippi and a missionary in Africa and Haiti. He became addicted to opioids after pharmaceutical representatives pitched them, she said. After a terrible decline, he died in 2015.

“I’m angry, I’m pissed, but I move on,” Adams said. “Because our society lost a person who could have made so many more contributions. … You took so much from us, but we plan to, through our faith in God, move forward.”

‘Scum of the earth’

Kristy Nelson played for the Sacklers a tense recording of a 911 call in which she summoned police to her home the day her son Bryan died of an opioid overdose. The dispatcher asked whether his skin had gone blue; she said it was white. She said she replays the call in her mind daily.

Thursday was Richard Sackler’s 77th birthday, according to public records. Later this month, Nelson said, she and her husband will visit the cemetery on what would have been Bryan’s 34th birthday.

“I understand today’s your birthday, Richard, how will you be celebrating?” she said. “I guarantee it won’t be in the cemetery. … You have truly benefitted from the death of children. You are scum of the earth.”

Her words echoed a 2001 email from Richard Sackler, made public during lawsuits over OxyContin, in which he referred to people with addiction as “scum of the earth.”

Jenny Scully, a nurse in New York, gave birth in 2014 while on OxyContin and other opioids prescribed years earlier when she was dealing with both breast cancer and injuries from an accident. She was told her baby would be healthy, Scully said, but the little girl has had a lifetime of physical, developmental and emotional difficulties.

“You have destroyed so many lives,” she said, pulling her daughter into view. “Take a good look at this beautiful little girl you robbed of the person she could have been.”

The forum was unconventional for the White Plains, New York, courtroom of Bankruptcy Judge Robert Drain, who on Wednesday gave tentative approval to key elements of a plan to settle thousands of lawsuits against the company.

Other drugmakers and wholesalers and even a consulting company have also been settling lawsuits over the opioid crisis, which has been linked two more than 500,000 deaths in the US over the past two decades. But Purdue’s case stands out because it was an early player with OxyContin and is privately owned.

‘When you created OxyContin, you created so much loss for so many people.I’m outraged that you haven’t owned up to the crisis that you’ve created.’

OxyContin victim’s mother Kay Scarpone

The settlement is estimated to be worth at least $US10 billion ($13.6 billion) over time. It calls for the Sacklers to contribute $US5.5 billion to $US6 billion over 17 years to fight the opioid crisis. That’s an increase of more than $US1 billion over a previous version rejected by another judge on appeal. Most of the money would be used for efforts to combat the crisis, but $US750 million would go directly to victims or their survivors.

The overall settlement, which still requires actions by multiple courts to take effect, provides more than $US150 million for Native American tribes and over $US100 million for medical monitoring and payments for children born in opioid withdrawal.

The plan also calls for family members to give up ownership of the company, so it can become a new entity, Knoa Pharma, with its profits dedicated to stemming the epidemic. In exchange, Sackler family members would get protection from lawsuits over opioids.

No apology

The family also agreed not to oppose any efforts to remove the Sackler name from cultural and educational institutions they have supported and to make public a larger cache of company documents.

Purdue Pharma starting selling OxyContin, a pioneering extended-release prescription painkiller, in 1996. At the same time, Purdue and other drug companies funded efforts to get doctors and other prescribers to think differently about opioids — suggesting they be used for some pain conditions for which the potent drugs were previously considered off limits.

Over the decades, there were waves of fatal overdoses, first associated with prescription drugs and then, as prescriptions became harder to obtain and some drugs became harder to manipulate for a quick high, from heroin. More recently, fentanyl and similar drugs have become the biggest killer.

Purdue has twice pleaded guilty to criminal charges, but no Sacklers have been charged with crimes. There are no indications any such charges are forthcoming, although seven US senators last month asked the US Department of Justice to consider charges.

Loading

The Sacklers have never unequivocally apologised. Last week, they released a statement saying in part, “while the families have acted lawfully in all respects, they sincerely regret that OxyContin, a prescription medicine that continues to help people suffering from chronic pain, unexpectedly became part of an opioid crisis that has brought grief and loss to far too many families and communities.”

Following the hearing, a spokesperson for Mortimer Sackler’s descendants said the family would not make a statement; a representative of Raymond Sackler’s side of the family did not immediately respond to a request for comment. The family of the other brother, Arthur, sold its share of Stamford, Connecticut-based Purdue before OxyContin was developed.

Several speakers noted the lack of an apology, and some called for prosecutors to pursue criminal investigations.

“When you created OxyContin, you created so much loss for so many people,” said Kay Scarpone, who lost her son Joseph, a former Marine, to addiction a month before his 26th birthday. “I’m outraged that you haven’t owned up to the crisis that you’ve created.”

AP

The Market Recap newsletter is a wrap of the day’s trading. Get it each weekday afternoon.